Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.14583 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Diagnostic Concordance of MyPath Melanoma Assay and PRAME Immunohistochemistry in Challenging Melanocytic Lesions.
Am J Dermatopathol
August 2025
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, NY.
Background: The 23-gene expression signature (GES) assay (myPath Melanoma) is a well-established molecular test for analyzing challenging melanocytic lesions, alongside fluorescence in situ hybridization (FISH) and single nucleotide polymorphism (SNP) array. However, routine use of these tests is often limited by high costs, long turnaround times, significant tissue requirements, and limited accessibility. This study aimed to evaluate the diagnostic concordance of PRAME immunohistochemistry (IHC) and the GES assay in difficult melanocytic lesions to determine whether PRAME IHC, widely available in pathology laboratories, could serve as a surrogate for GES.
View Article and Find Full Text PDFDermatologic findings after initiation of fingolimod in patients with multiple sclerosis: A real-world experience of five-year follow-up.
Mult Scler J Exp Transl Clin
August 2025
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Background: Fingolimod was approved in 2010 for the treatment of relapsing-remitting multiple sclerosis, generally as second-line therapy. While its efficacy in reducing the relapse rate is well-recognized, the dermatologic complications of fingolimod remain unexplored. Herein, we aimed to report our experience with multiple sclerosis patients treated with fingolimod who underwent periodic dermatologic examinations.
View Article and Find Full Text PDFPitfalls of biopsy margin assessment: Response to "Roland-McGowan JN et al. Development of a treatment decision aid for patients with dysplastic nevi who are candidates for re-excision.".
J Am Acad Dermatol
August 2025
Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut; Department of Dermatology, University of Florida, Gainesville, Florida.
Eruptive Disseminated Spitz Nevi With Architectural Features of Clark/Dysplastic Nevus.
Dermatol Pract Concept
July 2025
Department of Pathology of Israelita Albert Einstein Hospital, Sao Paulo, Brazil.
"DERMATOLOGIC SURGERY (GNP) GROUND AND POUND"- EXTENDABLE PLASTIC SURGERY WITH PRIMARY WOUND CLOSURE AS OPTIMAL TREATMENT OPTION FOR MIDDLE-SIZED CONGENITAL DYSPLASTIC NEVUS OF THE BACK OF AN 8-YEAR-OLD BOY.
Georgian Med News
May 2025
1Onkoderma - Clinic for Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
Surgical treatment of congenital melanocytic nevi is a serious problem for the relatives and "small patients" as well as for dermatosurgeons. The responsibility of the medical team is enormous, analogous to the expectations of the parents themselves. The aggressive dermatosurgical approach is usually short-lasting but effective and depends on the size and localization of the nevus as well as the experience of the dermatosurgeon.
View Article and Find Full Text PDF